Publications & Presentations

Taking Clues from Patients to Target Tumor-Associated Macrophages
Presentation by Kamal Puri, CSO

Targeting Tumor Myeloid Cells to Reshape the Immunosuppressive Microenvironment
Presentation by Kamal Puri, CSO

Poster 20:Discovery and preclinical characterization of dual antagonist antibodies targeting both LILRB1 and LILRB2 that enhance innate and adaptive anti-cancer immune responses

Targeting myeloid cells to overcome resistance to checkpoint inhibitor therapy
Presentation by Kamal Puri, CSO

Targeting myeloid cells to overcome suppression in the tumor microenvironment
Presentation by Kamal Puri, CSO

Poster 39: Interrogating Elite Responder humoral responses to identify novel targets and therapeutic antibodies for the treatment of cancer

Poster 498: Preclinical characterization of OR502, an anti-LILRB2 antibody that rescues innate and adaptive immune responses from LILRB2 mediated immune suppression

Targeting Tumor-Associated Macrophages to Reverse Immunosuppression in the Tumor Microenvironment
Presentation by Peter Probst, Senior Director of Immuno-Oncology

Interrogating the human memory B cell repertoire to discover novel targets, epitopes, and therapeutic antibodies
Presentation by Kamal Puri, CSO

Poster: Development of OR2805, an anti-CD163 antibody derived from an elite responder to checkpoint inhibitor therapy that relieves immunosuppression caused by M2c macrophages
Poster Presentation by Peter Probst, Senior Director of Immuno-Oncology

Reprogramming Human Macrophages to Relieve Immunosuppression in the Tumor Microenvironment
Presentation by Kamal Puri, CSO

Discovery and Development of Antibodies to Relieve Immunosuppression in the Tumor Microenvironment
Presentation by Kamal Puri, CSO

Poster 271: Development of OR2805, an anti-CD163 antibody derived from an elite responder to checkpoint inhibitor therapy that relieves immunosuppression caused by M2c macrophages

Poster 262: Preclinical characterization of humanized anti-Siglec-15 antibodies that rescue T cells from macrophage-mediated immune suppression

Poster 276: Discovery and preclinical characterization of anti-LILRB2 antibodies that rescue T cells from macrophage-mediated immune suppression

Using the Human Immune System to Identify Antibodies that Modulate the Tumor Microenvironment
Presentation by Kamal Puri, CSO

|Watch the Oral Presentation|

Abstract 1719: OR2805, an anti-CD163 antibody derived from an elite responder to checkpoint inhibitor therapy relieves immunosuppression caused by tumor associated macrophages

Abstract 1638: Discovery and preclinical characterization of anti-Siglec-15 antibodies that rescue T cells from macrophage-mediated immune suppression

Using the Human Immune System to Identify Antibodies that Modulate the Tumor Microenvironment
Presentation by Kamal Puri, CSO

|Watch the Oral Presentation|

Poster 490: Antibody derived from an elite responder to checkpoint inhibitor therapy relieves immunosuppression by tumor associated macrophage